How should we manage patients with a history of gastrointestinal bleeding who require anticoagulant treatment because of a high CHA2DS2-VASc score? Should we prefer novel oral anticoagulants in such patients?
What is the optimal approach to anticoagulant treatment in patients with a high bleeding risk? How should we estimate the bleeding risk and adjust anticoagulant treatment to the bleeding risk?
How can we adequately assess the risk of recurrent thrombosis? What is the Vienna Prediction Model?
Is there an association between novel oral anticoagulants, acute coronary syndromes, and the risk of myocardial infarction?
How to approach a patient treated with novel oral anticoagulants who develops bleeding or in whom an urgent surgery is necessary?
How to manage patients treated with novel oral anticoagulants who require surgery?
Should the D-dimer concentration be taken into account when considering discontinuation of anticoagulants following a thrombotic event?
The role of aspirin in prophylaxis of venous thrombosis is being reevaluated every few years. What is the evidence for the use of aspirin in primary and secondary prophylaxis of venous thrombosis?
Is there any evidence suggesting benefits of D-dimer monitoring in patients with cancer or chronic diseases? As we know that chronic diseases cause elevation in D-dimer levels, should we still measure this parameter to exclude thrombosis?
Are there any important differences in risk stratification, prophylaxis, and treatment of thrombosis in patients with cancer vs patients with nonneoplastic diseases?
English
Polski
Español
українська